Neomorph secured a $100 million Series B round to advance its oral molecular glue degrader NEO-811 through clinical development and support broader pipeline progress. The company plans continued work on a Phase I/II trial (NCT07300241) in locally advanced or metastatic non-resectable clear cell renal cell carcinoma (ccRCC), targeting ARNT (HIF-1β). In the funding announcement, Neomorph emphasized the biology of the HIF pathway and the high prevalence of VHL loss in ccRCC, positioning ARNT degradation as a way to disrupt downstream signaling. Beyond NEO-811, the company said additional capital will fund multiple molecular-glue candidates across therapeutic areas. The financing also highlights how molecular glue modality developers are attracting follow-on interest when early clinical execution is underway, especially in oncology where pathway dependencies provide clear mechanistic hooks.